Loading color scheme

News

TEDCO Invests $800,000 into Innovative Tech and Life Science Startups

The Maryland Technology Development Corporation (TEDCO) announced today that six companies, including Virtici spinout Rise Therapeutics, received a total of $800,000 in seed funding. 

Read more

Virtici Announces a New Spin-Out Focused on Microbiome Platform Technologies

Virtici, LLC announced today the spin-out of a new drug development company, Rise Therapeutics, which is focused on developing microbiome-based, immunological therapies. To form the spin-out, Rise obtained key microbiome-related intellectual property and technologies incubated at Virtici to support the development of first-in-class, orally-delivered, biological medicines.

Read more

Cardio3 Biosciences Acquires OnCyte CAR T-Cell Portfolio from Celdara Medical

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced the acquisition of OnCyte, LLC a division of Celdara Medical, and its portfolio of immuno-oncology CAR T cell product candidates.

Read more

Celdara Medical Updates CAR-T Cell Agreement with Celyad

Celdara Medical, LLC today announced that it has successfully concluded negotiations with Celyad SA (Euronext Brussels and Paris, and NASDAQ:CYAD) related to their ongoing partnership for discovery and development of CAR T cell therapies.

Read more

Virtici, Celdara Medical, and MBV Announce Collaboration

Today Virtici, Celdara Medical and MBV announced their formation of the first collaborative nationwide network for the development of early stage biotechnologies. The goals are simple: to improve human health by identifying the highest potential innovations in medicine and developing them into the clinic.

Read more

Virtici Launches Collaboration to Identify and Progress High Potential Preclinical Therapeutics

Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.

Read more